Nektar Therapeutics presented a quarter with significant advancements in their REZPEG studies and a strong financial position. However, the ongoing litigation with Lilly and non-cash losses from an equity investment present challenges.

Company Guidance -

Q2 2025

During Nektar Therapeutics' Q1 2025 financial results call, the company provided guidance regarding multiple metrics related to their pipeline and financial health. They highlighted the progress of their immunology pipeline, focusing on the advancement of rezpegaldesleukin (REZPEG) in three Phase 2 studies. The REZOLVE-AD Phase 2b study, with 400 patients, aims to establish safety and efficacy in atopic dermatitis, with results from the 16-week induction period expected in June 2025. They also discussed the REZPEG-AA Phase 2b study in alopecia areata, targeting a December 2025 data release. Financially, the company maintains a strong position with $220.7 million in cash and no debt, projecting a cash runway into Q4 2026. They expect 2025 revenue to be around $40 million, with R&D expenses between $110 million and $120 million. The company is preparing for a quiet period in June ahead of the REZPEG data release.

Advancement of REZPEG in Phase 2 Studies

Nektar is advancing rezpegaldesleukin (REZPEG) in three separate Phase 2 studies, including atopic dermatitis, alopecia areata, and Type 1 diabetes. The REZOLVE-AD study for atopic dermatitis has enrolled 400 patients, and top-line results are expected in June 2025.

Strong Financial Position

Nektar ended Q1 2025 with $220.7 million in cash and investments and no debt, projecting a runway into Q4 2026.

Progress in Early-Stage Immunology Pipeline

The IND-enabling studies for NKTR-0165, a TNFR2 agonist antibody, are on track for completion in 2025, with plans to submit an IND filing.

Upcoming Data Presentations

Data from the NKTR-255 oncology program will be presented at the European Hematology Association Congress.

Nektar Therapeutics (NKTR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NKTR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 07, 2025	2025 (Q2)	-3.03 / -	-3.75	―	―	―
May 08, 2025	2025 (Q1)	-2.56 / -3.60	-2.85	-26.32% (-0.75)	―
Mar 12, 2025	2024 (Q4)	-2.03 / 0.45	-3.3	113.64% (+3.75)	―
Nov 07, 2024	2024 (Q3)	-2.98 / -2.70	-3.6	25.00% (+0.90)	―
Aug 08, 2024	2024 (Q2)	-2.77 / -3.75	-4.05	7.41% (+0.30)	―
May 09, 2024	2024 (Q1)	-2.85 / -2.85	-10.95	73.97% (+8.10)	―
Mar 04, 2024	2023 (Q4)	-3.16 / -3.30	-4.8	31.25% (+1.50)	―
Nov 07, 2023	2023 (Q3)	-2.98 / -3.60	-4.65	22.58% (+1.05)	―
Aug 08, 2023	2023 (Q2)	-4.22 / -4.05	-12.75	68.24% (+8.70)	―
May 09, 2023	2023 (Q1)	-3.72 / -10.95	-7.35	-48.98% (-3.60)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NKTR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 08, 2025	$9.28	$8.83	-4.85%
Mar 12, 2025	$12.30	$12.23	-0.57%
Nov 07, 2024	$20.55	$21.00	+2.19%
Aug 08, 2024	$18.15	$16.65	-8.26%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Nektar Therapeutics (NKTR) report earnings?

Nektar Therapeutics (NKTR) is schdueled to report earning on Aug 07, 2025, After Close (Confirmed).

What is Nektar Therapeutics (NKTR) earnings time?

Nektar Therapeutics (NKTR) earnings time is at Aug 07, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NKTR EPS forecast?

NKTR EPS forecast for the fiscal quarter 2025 (Q2) is -3.03.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing